Phase II study of irinotecan in patients with chemotherapy pretreated angiosarcoma.

Phase II study of irinotecan in patients with chemotherapy pretreated angiosarcoma. - CPT-11 for angiosarcoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008187

Enrollment

Registered

2012-06-20

Start date

2010-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angiosarcoma

Interventions

irinotecan 100 mg/m-2 (day 1, 8, 15/q4 weeks) until intorelable toxicities or disease progression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) age => 18 years old b) Performance status 0 to 2 c) no abnormal findings on ECG d) no massive ascitis and ileus e) appropriate organ function 1) WBC 3,000/mm-3 => or ANC => 1,500/mm-3 , Platelet => 100,000/mm-3 2) AST =< 100 IU/L or ALT =< 100 IU/L 3) Total bilirubin < 2.0mg/dL 4) Creatinine < 1.5mg/dL f) no prior chemotherapy of irinotecan and topotecan g) informed concent

Exclusion criteria

Exclusion criteria: a) pregnancy b) severe infection c) interstitual peumonia or lungfibrosis d) symptomatic CNS metastasis e) HIV infection

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
progression-free survival, overall survival, adverse events	—

Countries

Japan

Contacts

Public ContactKan Yonemori

National Cancer Center Hospital Breast and Medical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026